Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR9 | Q9NR96 | 2/20 | 0.68 |
| ▸ | MGLL | Q99685 | 17/20 | 0.56 |
| ▸ | FAAH | O00519 | 5/20 | 0.50 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | CCR6 | P51684 | 1/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9067136 | 0.85 | MGLL (0.68) | TLR9MGLLFAAHHSP90AA1ALDH1A1 | |
| SCHEMBL10769331 | 0.82 | MGLL (0.73) | TLR9MGLLFAAHHSP90AA1ALDH1A1 | |
| SCHEMBL121404 | 0.81 | TLR9 (1.00) | TLR9MGLLFAAHHSP90AA1ALDH1A1 | |
| SCHEMBL29377102 | 0.81 | TLR9 (1.00) | TLR9MGLLFAAHHSP90AA1ALDH1A1 | |
| SCHEMBL28343039 | 0.80 | ALDH1A1 (0.56) | TLR9MGLLFAAHHSP90AA1ALDH1A1 | |
| SCHEMBL28624878 | 0.80 | MGLL (0.73) | TLR9MGLLFAAHHSP90AA1ALDH1A1 | |
| SCHEMBL3277562 | 0.80 | TLR9 (0.68) | TLR9MGLLFAAHHSP90AA1ALDH1A1 | |
| SCHEMBL31179969 | 0.80 | TLR9 (0.68) | TLR9MGLLFAAHHSP90AA1ALDH1A1 | |
| SCHEMBL144793 | 0.78 | MGLL (0.65) | TLR9MGLLFAAHHSP90AA1ALDH1A1 | |
| SCHEMBL4604629 | 0.78 | MGLL (0.53) | TLR9MGLLFAAHHSP90AA1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 225 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11912794-B2 | Modulation of structured polypeptide specificity | Bicyclerd Limited (GB) | 2024-02-27 | — | — | US | claimed |
| US-20210122786-A1 | MODULATION OF STRUCTURED POLYPEPTIDE SPECIFICITY | Bicyclerd Limited (GB) | 2021-04-29 | — | — | US | claimed |
| US-10800813-B2 | Modulation of structured polypeptide specificity | Bicyclerd Limited (GB) | 2020-10-13 | — | — | US | claimed |
| US-20260137791-A1 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR PD-L1 | Bicyclerd Limited (GB) | 2026-05-21 | — | — | US | disclosed |
| US-12630588-B2 | Bicyclic peptide ligands specific for CD137 | BICYCLETX LIMITED (GB) | 2026-05-19 | — | — | US | disclosed |
| US-12551567-B2 | Bicyclic peptide ligands specific for PD-L1 | Bicyclerd Limited (GB) | 2026-02-17 | — | — | US | disclosed |
| US-12540161-B2 | Linkers | BICYCLETX LIMITED (GB) | 2026-02-03 | — | — | US | disclosed |
| US-12491253-B2 | Bicyclic peptide ligands specific for MT1-MMP | Bicyclerd Limited (GB) | 2025-12-09 | — | — | US | disclosed |
| US-20250325672-A1 | ANTI-INFECTIVE BICYCLIC PEPTIDE LIGANDS | BICYCLE TX LTD (GB) | 2025-10-23 | — | — | US | disclosed |
| US-20250255975-A1 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR MT1-MMP | Bicyclerd Limited (GB) | 2025-08-14 | — | — | US | disclosed |
| US-12377155-B2 | Bicyclic peptide ligands specific for PSMA | Bicyclerd Limited (GB) | 2025-08-05 | — | — | US | disclosed |
| US-20120172235-A1 | PEPTIDE LIBRARIES | MEDICAL RESEARCH COUNCIL (GB) | 2012-07-05 | — | — | US | disclosed |
| EP-2464727-A2 | PEPTIDE LIBRARIES | Medical Research Council (GB) | 2012-06-20 | — | — | EP | disclosed |
| US-20120101256-A1 | MULTISPECIFIC PEPTIDES | MEDICAL RESEARCH COUNCIL (GB) | 2012-04-26 | — | — | US | disclosed |
| EP-2257624-B1 | METHODS AND COMPOSITIONS | MEDICAL RES COUNCIL (GB) | 2012-04-25 | — | — | EP | disclosed |
| EP-2420255-A2 | Polypeptide inhibitors of urokinase type plasminogen activator | Ecole Polytechnique Federale De Lausanne (EPFL) (CH) | 2012-02-22 | — | — | EP | disclosed |
| EP-2393519-A1 | MULTISPECIFIC PEPTIDES | Medical Research Council (GB) | 2011-12-14 | — | — | EP | disclosed |
| WO-2011018227-A2 | PEPTIDE LIBRARIES | MEDICAL RESEARCH COUNCIL (GB) | 2011-02-17 | — | — | WO | disclosed |
| US-20100317547-A1 | METHODS AND COMPOSITIONS | MEDICAL RESEARCH COUNCIL | 2010-12-16 | — | — | US | disclosed |
| WO-2010089115-A1 | MULTISPECIFIC PEPTIDES | MEDICAL RESEARCH COUNCIL (GB) | 2010-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250325672-A1 | ANTI-INFECTIVE BICYCLIC PEPTIDE LIGANDS | ACE2, SARS1, TMPRSS2 | TLR9 1431/4885MGLL 1540/4885FAAH 2378/4885 |
| US-20120172235-A1 | PEPTIDE LIBRARIES | MICA, SPPL2B, PTMS | TLR9 2208/4885MGLL 3288/4885FAAH 3698/4885 |
| US-12630588-B2 | Bicyclic peptide ligands specific for CD137 | PTMS, IL36G, HLA-A | TLR9 1302/4885MGLL 3904/4885FAAH 2721/4885 |
| US-20250255975-A1 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR MT1-MMP | MMEL1, MMP3, TIMP3 | TLR9 1652/4885MGLL 2818/4885FAAH 2906/4885 |
| US-12551567-B2 | Bicyclic peptide ligands specific for PD-L1 | PDCD1LG2, CD274, PDCD1 | TLR9 2606/4885MGLL 4463/4885FAAH 4234/4885 |
| US-20260137791-A1 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR PD-L1 | PDCD1LG2, CD274, PDCD1 | TLR9 610/4885MGLL 4463/4885FAAH 3785/4885 |
| US-10800813-B2 | Modulation of structured polypeptide specificity | KLKB1, KLK5, KLK1 | TLR9 4604/4885MGLL 2429/4885FAAH 3421/4885 |
| US-20120101256-A1 | MULTISPECIFIC PEPTIDES | TIMCC, MICA, LNPEP | TLR9 1897/4885MGLL 3315/4885FAAH 3891/4885 |
| US-12377155-B2 | Bicyclic peptide ligands specific for PSMA | KLK3, FOLH1, PSMA3 | TLR9 1615/4885MGLL 2917/4885FAAH 3284/4885 |
| US-12491253-B2 | Bicyclic peptide ligands specific for MT1-MMP | MMEL1, MMP3, TIMP3 | TLR9 1584/4885MGLL 4053/4885FAAH 3353/4885 |
| US-12540161-B2 | Linkers | ADM2, CDA, DCTD | TLR9 1391/4885MGLL 4027/4885FAAH 134/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.